Li-Zhen Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Li-Zhen Yang has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Frank R. Heinzel
Division of Cardiology, Medical University of Graz, Auenbruggerplatz, Graz, Austria
2 shared publicationsStefanie Walther
Division of Cardiology, Medical University of Graz, Auenbruggerplatz, Graz, Austria
2 shared publicationsB-R Jiang
1 shared publicationBernhard Doleschal
Division of Cardiology, Medical University of Graz, Auenbruggerplatz, Graz, Austria
1 shared publicationBing Han
Division of Endocrinology and Metabolism, Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
1 shared publicationBo-Ren Jiang
Division of Endocrinology and Metabolism, Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
1 shared publication
Latest Publications
- Open Access
- 1 February 2022
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 15, 545-555
Liver Enzymes are Associated with Hyperglycemia in Diabetes: A Three-Year Retrospective Study
Purpose: The correlation between liver enzymes and blood glucose in diabetes mellitus remains unclear. The purpose of present three-year retrospective study was to explore the association between liver enzymes and glycemia in type 2 diabetes mellitus (T2DM). Patients and Methods: 2046 participants (non-fatty liver, n=1253; fatty liver, n=793) with T2DM were included in our study. For all these patients, related basic clinical information, biochemical parameters and liver ultrasonic data were collected. The effects of liver enzymes on blood glucose levels were analysed by linear and binary logistic regression models. Results: In the comparative analyses between groups, gamma-glutamyltransferase (GGT) and serum alkaline phosphatase (AKP) levels increased with glycosylated haemoglobin A1c (HbA1c) concentration, but alanine aminotransferase and aspartate aminotransferase did not show the same trend. Adjusted for possible confounding factors, the linear regression models indicated the strong positive correlations between Log10 AKP, Log10 GGT and three blood glucose parameters (fasting glucose, postprandial glucose, and HbA1c) (all P< 0.01). And such correlations were more significant in the subgroups of fatty liver. Multivariate binary logistic regression showed that the ORs increased by 1.01 times higher per Log10 AKP unit in the highest blood glucose tertile (P< 0.01). Conclusion: GGT and especially AKP can aggravate hyperglycemia in T2DM patients, which provides new clues for the research and treatment of T2DM.
- 1 February 2022
- Published by Taylor & Francis in Diabetes, Metabolic Syndrome and Obesity
- Vol. ume 15, 545-555
Open AccessLiver Enzymes are Associated with Hyperglycemia in Diabetes: A Three-Year Retrospective Study
Purpose: The correlation between liver enzymes and blood glucose in diabetes mellitus remains unclear. The purpose of present three-year retrospective study was to explore the association between liver enzymes and glycemia in type 2 diabetes mellitus (T2DM). Patients and Methods: 2046 participants (non-fatty liver, n=1253; fatty liver, n=793) with T2DM were included in our study. For all these patients, related basic clinical information, biochemical parameters and liver ultrasonic data were collected. The effects of liver enzymes on blood glucose levels were analysed by linear and binary logistic regression models. Results: In the comparative analyses between groups, gamma-glutamyltransferase (GGT) and serum alkaline phosphatase (AKP) levels increased with glycosylated haemoglobin A1c (HbA1c) concentration, but alanine aminotransferase and aspartate aminotransferase did not show the same trend. Adjusted for possible confounding factors, the linear regression models indicated the strong positive correlations between Log10 AKP, Log10 GGT and three blood glucose parameters (fasting glucose, postprandial glucose, and HbA1c) (all P< 0.01). And such correlations were more significant in the subgroups of fatty liver. Multivariate binary logistic regression showed that the ORs increased by 1.01 times higher per Log10 AKP unit in the highest blood glucose tertile (P< 0.01). Conclusion: GGT and especially AKP can aggravate hyperglycemia in T2DM patients, which provides new clues for the research and treatment of T2DM.
- Open Access
- 1 April 2019
- Published by SAGE Publications in Dose-Response
- Vol. 17 (2)
Research on the Effects of the Chronic Treatment With Different Doses of Urocortin 2 in Heart Failure Rats
Corticotropin-releasing factor (CRF) receptor type 2 (CRF2) exists in both cardiomyocytes and neurocytes. The purpose of this research was to explore if chronic treatment with urocortin 2 (UCN2), a CRF2 receptor agonist, at different doses can improve prognosis and regulate the expression of CRF2 receptor and calcium handling proteins without any adverse effects on behavior in heart failure. Heart failure was established in Sprague-Dawley rats and was confirmed by echocardiography. Heart failure rats were injected intraperitoneally with UCN2 (5, 10, or 20 µg·kg−1·d−1) for 30 days. Survival rate, cardiac function, expressions of cardiac CRF2 receptor, RyR2, SERCA2, and hypothalamic and hippocampal c-FOS, CRF receptor type 1 (CRF1) and CRF2 receptor were determined. Behavior was evaluated by Morris Water-Maze and Open-Field tests. Results showed that chronic peripheral UCN2 treatment improved survival rate in a dose–response manner and increased cardiac function and expression of CRF2 receptor and SERCA2 in heart failure, especially at the high dosage. Moreover, cellular-fos (c-FOS), CRF1 receptor, and CRF2 receptor expressions of both hypothalamic and hippocampal tissues were significantly increased in high dosage group. Furthermore, the behavior tests suggested that chronic UCN2 treatment did not exacerbate stress/anxiety-like behavior in HF. In conclusion, chronic peripheral treatment with UCN2 increases survival in a dose–response manner in heart failure rats without inducing stress/anxiety-like behavior.
- 1 April 2019
- Published by SAGE Publications in Dose-Response
- Vol. 17 (2)
Open AccessResearch on the Effects of the Chronic Treatment With Different Doses of Urocortin 2 in Heart Failure Rats
Corticotropin-releasing factor (CRF) receptor type 2 (CRF2) exists in both cardiomyocytes and neurocytes. The purpose of this research was to explore if chronic treatment with urocortin 2 (UCN2), a CRF2 receptor agonist, at different doses can improve prognosis and regulate the expression of CRF2 receptor and calcium handling proteins without any adverse effects on behavior in heart failure. Heart failure was established in Sprague-Dawley rats and was confirmed by echocardiography. Heart failure rats were injected intraperitoneally with UCN2 (5, 10, or 20 µg·kg−1·d−1) for 30 days. Survival rate, cardiac function, expressions of cardiac CRF2 receptor, RyR2, SERCA2, and hypothalamic and hippocampal c-FOS, CRF receptor type 1 (CRF1) and CRF2 receptor were determined. Behavior was evaluated by Morris Water-Maze and Open-Field tests. Results showed that chronic peripheral UCN2 treatment improved survival rate in a dose–response manner and increased cardiac function and expression of CRF2 receptor and SERCA2 in heart failure, especially at the high dosage. Moreover, cellular-fos (c-FOS), CRF1 receptor, and CRF2 receptor expressions of both hypothalamic and hippocampal tissues were significantly increased in high dosage group. Furthermore, the behavior tests suggested that chronic UCN2 treatment did not exacerbate stress/anxiety-like behavior in HF. In conclusion, chronic peripheral treatment with UCN2 increases survival in a dose–response manner in heart failure rats without inducing stress/anxiety-like behavior.
- 10 September 2018
- Published by Springer Nature in Endocrine
- Vol. 62 (3) , 546-551
Ectopic thyroids have lower computed tomography attenuation values than orthotopic thyroids
To determine whether ectopic thyroid had the same computed tomography (CT) value as orthotopic thyroid.
- 10 September 2018
- Published by Springer Nature in Endocrine
- Vol. 62 (3) , 546-551
Ectopic thyroids have lower computed tomography attenuation values than orthotopic thyroids
To determine whether ectopic thyroid had the same computed tomography (CT) value as orthotopic thyroid.
- 26 June 2018
- Published by Georg Thieme Verlag KG in Experimental and Clinical Endocrinology & Diabetes
- Vol. 126 (08) , 493-504
The Association Between the Levels of Thyroid Hormones and Peripheral Nerve Conduction in Patients with Type 2 Diabetes Mellitus
Background Type 2 diabetes has an underlying pathology with thyroid dysfunction. However, few studies have investigated the association between thyroid hormones and diabetic peripheral neuropathy. Our aim was to evaluate the relationship between thyroid hormones and electrophysiological properties of peripheral nerves in type 2 diabetes. Patients and Methods The medical records of 308 patients with type 2 diabetes were enrolled in this study. Subjects stratified by sex were divided into subgroups based on the diagnosis of nerve conduction study. The nerve conduction parameters were separately described with the spectrum of thyroid hormones. Multivariate regression models to analyze the potential links between thyroid hormones and nerve conduction parameters. Results The serum free triiodine thyronine levels between normal and abnormal nerve conduction groups were statistically different in total (4.55±0.65 vs 4.37±0.63, P<0.05) and female diabetic patients (4.46±0.50 vs 4.14±0.57, P<0.01). Moreover, the summed amplitude and velocity Z score of female and male increased with free triiodine thyronine levels (P<0.05). Sex-specific binary logistic regression models showed that free triiodine thyronine levels were associated with decreased odds of abnormal nerve conduction diagnosis (odds ratio [95%CI]=0.151[0.047-0.186]) and low tertile of summed amplitude Z score (odds ratio [95%CI]=0.283[0.099-0.809]) in female. In total patients, free triiodine thyronine level was negatively associated with odds of abnormal nerve conduction (odds ratio [95%CI]=0.436 [0.226-0.842]), low tertile of summed velocity (odds ratio [95%CI]=0.44[0.226-0.858]) and amplitude (odds ratio [95%CI]=0.436[0.227-0.838) Z score. Conclusions Serum free triiodine thyronine level is associated with nerve conduction in diabetes. Low free triiodine thyronine may be a potential risk for diabetic peripheral neuropathy.
- 26 June 2018
- Published by Georg Thieme Verlag KG in Experimental and Clinical Endocrinology & Diabetes
- Vol. 126 (08) , 493-504
The Association Between the Levels of Thyroid Hormones and Peripheral Nerve Conduction in Patients with Type 2 Diabetes Mellitus
Background Type 2 diabetes has an underlying pathology with thyroid dysfunction. However, few studies have investigated the association between thyroid hormones and diabetic peripheral neuropathy. Our aim was to evaluate the relationship between thyroid hormones and electrophysiological properties of peripheral nerves in type 2 diabetes. Patients and Methods The medical records of 308 patients with type 2 diabetes were enrolled in this study. Subjects stratified by sex were divided into subgroups based on the diagnosis of nerve conduction study. The nerve conduction parameters were separately described with the spectrum of thyroid hormones. Multivariate regression models to analyze the potential links between thyroid hormones and nerve conduction parameters. Results The serum free triiodine thyronine levels between normal and abnormal nerve conduction groups were statistically different in total (4.55±0.65 vs 4.37±0.63, P<0.05) and female diabetic patients (4.46±0.50 vs 4.14±0.57, P<0.01). Moreover, the summed amplitude and velocity Z score of female and male increased with free triiodine thyronine levels (P<0.05). Sex-specific binary logistic regression models showed that free triiodine thyronine levels were associated with decreased odds of abnormal nerve conduction diagnosis (odds ratio [95%CI]=0.151[0.047-0.186]) and low tertile of summed amplitude Z score (odds ratio [95%CI]=0.283[0.099-0.809]) in female. In total patients, free triiodine thyronine level was negatively associated with odds of abnormal nerve conduction (odds ratio [95%CI]=0.436 [0.226-0.842]), low tertile of summed velocity (odds ratio [95%CI]=0.44[0.226-0.858]) and amplitude (odds ratio [95%CI]=0.436[0.227-0.838) Z score. Conclusions Serum free triiodine thyronine level is associated with nerve conduction in diabetes. Low free triiodine thyronine may be a potential risk for diabetic peripheral neuropathy.
- 15 June 2018
- Published by Springer Nature in Science China Life Sciences
- Vol. 61 (8) , 988-991
Amplitude of peroneal compound motor action potential increases in type 2 diabetes with thyroid autoimmunity
- 15 June 2018
- Published by Springer Nature in Science China Life Sciences
- Vol. 61 (8) , 988-991
Amplitude of peroneal compound motor action potential increases in type 2 diabetes with thyroid autoimmunity
- 1 June 2017
- Published by Elsevier in Public Health
- Vol. 147, 59-65
Magnitude of and gender differences in cardiovascular risk profiles among community residents in Shenzhen, China
- 1 June 2017
- Published by Elsevier in Public Health
- Vol. 147, 59-65
Magnitude of and gender differences in cardiovascular risk profiles among community residents in Shenzhen, China
- 1 July 2015
- Published by Elsevier in European Journal of Pharmacology
- Vol. 758, 97-106
Urocortin2 prolongs action potential duration and modulates potassium currents in guinea pig myocytes and HEK293 cells
- 1 July 2015
- Published by Elsevier in European Journal of Pharmacology
- Vol. 758, 97-106
Urocortin2 prolongs action potential duration and modulates potassium currents in guinea pig myocytes and HEK293 cells
- 14 December 2010
- Published by Wiley in British Journal of Pharmacology
- Vol. 162 (2) , 544-556
cAMP‐ and Ca2+/calmodulin‐dependent protein kinases mediate inotropic, lusitropic and arrhythmogenic effects of urocortin 2 in mouse ventricular myocytes
BACKGROUND AND PURPOSE Urocortin 2 is beneficial in heart failure, but the underlying cellular mechanisms are not completely understood. Here we have characterized the functional effects of urocortin 2 on mouse cardiomyocytes and elucidated the underlying signalling pathways and mechanisms.EXPERIMENTAL APPROACH Mouse ventricular myocytes were field‐stimulated at 0.5 Hz at room temperature. Fractional shortening and [Ca2+]i transients were measured by an edge detection and epifluorescence system respectively. Western blots were carried out on myocyte extracts with antibodies against total phospholamban (PLN) and PLN phosphorylated at serine‐16.KEY RESULTS Urocortin 2 elicited time‐ and concentration‐dependent positive inotropic and lusitropic effects (EC50: 19 nM) that were abolished by antisauvagine‐30 (10 nM, n= 6), a specific antagonist of corticotrophin releasing factor (CRF) CRF2 receptors. Urocortin 2 (100 nM) increased the amplitude and decreased the time constant of decay of the underlying [Ca2+]i transients. Urocortin 2 also increased PLN phosphorylation at serine‐16. H89 (2 µM) or KT5720 (1 µM), two inhibitors of protein kinase A (PKA), as well as KN93 (1 µM), an inhibitor of Ca2+/calmodulin‐dependent protein kinase II (CaMKII), suppressed the urocortin 2 effects on shortening and [Ca2+]i transients. In addition, urocortin 2 also elicited arrhythmogenic events consisting of extra cell shortenings and extra [Ca2+]i increases in diastole. Urocortin 2‐induced arrhythmogenic events were significantly reduced in cells pretreated with KT5720 or KN93.CONCLUSIONS AND IMPLICATIONS Urocortin 2 enhanced contractility in mouse ventricular myocytes via activation of CRF2 receptors in a cAMP/PKA‐ and Ca2+/CaMKII‐dependent manner. This enhancement was accompanied by Ca2+‐dependent arrhythmogenic effects mediated by PKA and CaMKII.
- 14 December 2010
- Published by Wiley in British Journal of Pharmacology
- Vol. 162 (2) , 544-556
cAMP‐ and Ca2+/calmodulin‐dependent protein kinases mediate inotropic, lusitropic and arrhythmogenic effects of urocortin 2 in mouse ventricular myocytes
BACKGROUND AND PURPOSE Urocortin 2 is beneficial in heart failure, but the underlying cellular mechanisms are not completely understood. Here we have characterized the functional effects of urocortin 2 on mouse cardiomyocytes and elucidated the underlying signalling pathways and mechanisms.EXPERIMENTAL APPROACH Mouse ventricular myocytes were field‐stimulated at 0.5 Hz at room temperature. Fractional shortening and [Ca2+]i transients were measured by an edge detection and epifluorescence system respectively. Western blots were carried out on myocyte extracts with antibodies against total phospholamban (PLN) and PLN phosphorylated at serine‐16.KEY RESULTS Urocortin 2 elicited time‐ and concentration‐dependent positive inotropic and lusitropic effects (EC50: 19 nM) that were abolished by antisauvagine‐30 (10 nM, n= 6), a specific antagonist of corticotrophin releasing factor (CRF) CRF2 receptors. Urocortin 2 (100 nM) increased the amplitude and decreased the time constant of decay of the underlying [Ca2+]i transients. Urocortin 2 also increased PLN phosphorylation at serine‐16. H89 (2 µM) or KT5720 (1 µM), two inhibitors of protein kinase A (PKA), as well as KN93 (1 µM), an inhibitor of Ca2+/calmodulin‐dependent protein kinase II (CaMKII), suppressed the urocortin 2 effects on shortening and [Ca2+]i transients. In addition, urocortin 2 also elicited arrhythmogenic events consisting of extra cell shortenings and extra [Ca2+]i increases in diastole. Urocortin 2‐induced arrhythmogenic events were significantly reduced in cells pretreated with KT5720 or KN93.CONCLUSIONS AND IMPLICATIONS Urocortin 2 enhanced contractility in mouse ventricular myocytes via activation of CRF2 receptors in a cAMP/PKA‐ and Ca2+/CaMKII‐dependent manner. This enhancement was accompanied by Ca2+‐dependent arrhythmogenic effects mediated by PKA and CaMKII.
- Open Access
- 1 February 2006
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 69 (2) , 402-411
Urocortin II enhances contractility in rabbit ventricular myocytes via CRF2 receptor-mediated stimulation of protein kinase A
Objective: Urocortin II (UcnII), a peptide of the corticotropin-releasing factor (CRF) family, exerts profound actions on the cardiovascular system. Direct effects of UcnII on adult cardiomyocytes have not been evaluated before. Our aim was to characterize functional effects of UcnII on cardiomyocytes and to elucidate the underlying signaling pathway(s) and cellular mechanisms. Methods: Rabbit ventricular cardiomyocytes were stimulated at 0.5 Hz (22–25 °C). Unloaded cell shortening (FS, edge detection), [Ca2+]i transients (Fluo-4), and L-type Ca2+ currents (ICa, whole-cell patch clamping) were measured. Sarcoplasmic reticulum (SR) Ca2+ load was assessed by rapid application of caffeine (20 mmol/L). Results: UcnII increased cell shortening and accelerated relaxation in a time- and concentration-dependent manner (EC50: 10.7 nmol/L). The inotropic effect of UcnII was maximal at 100 nmol/L (35% ± 11% increase in FS, n=8, P2 receptors (10 nmol/L antisauvagine-30, n=5) or protein kinase A (PKA, 500 nmol/L H-89, n=5). UcnII increased [Ca2+]i transient amplitude (by 63% ± 35%, n=7, Pn=7, P2+ load (by 19% ± 7%, n=7, P2+ release (from 57% ± 7% to 98% ± 2%, n=7, PICa was augmented by 32.7% ± 10.0% (n=9, PICa–V relationship was shifted by −15 mV during UcnII treatment. Conclusion: UcnII exerts positive inotropic and lusitropic effects in cardiomyocytes via CRF2 receptor-mediated stimulation of PKA which augments ICa and SR Ca2+ load to increase SR Ca2+ release and [Ca2+]i transients.
- 1 February 2006
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 69 (2) , 402-411
Open AccessUrocortin II enhances contractility in rabbit ventricular myocytes via CRF2 receptor-mediated stimulation of protein kinase A
Objective: Urocortin II (UcnII), a peptide of the corticotropin-releasing factor (CRF) family, exerts profound actions on the cardiovascular system. Direct effects of UcnII on adult cardiomyocytes have not been evaluated before. Our aim was to characterize functional effects of UcnII on cardiomyocytes and to elucidate the underlying signaling pathway(s) and cellular mechanisms. Methods: Rabbit ventricular cardiomyocytes were stimulated at 0.5 Hz (22–25 °C). Unloaded cell shortening (FS, edge detection), [Ca2+]i transients (Fluo-4), and L-type Ca2+ currents (ICa, whole-cell patch clamping) were measured. Sarcoplasmic reticulum (SR) Ca2+ load was assessed by rapid application of caffeine (20 mmol/L). Results: UcnII increased cell shortening and accelerated relaxation in a time- and concentration-dependent manner (EC50: 10.7 nmol/L). The inotropic effect of UcnII was maximal at 100 nmol/L (35% ± 11% increase in FS, n=8, P2 receptors (10 nmol/L antisauvagine-30, n=5) or protein kinase A (PKA, 500 nmol/L H-89, n=5). UcnII increased [Ca2+]i transient amplitude (by 63% ± 35%, n=7, Pn=7, P2+ load (by 19% ± 7%, n=7, P2+ release (from 57% ± 7% to 98% ± 2%, n=7, PICa was augmented by 32.7% ± 10.0% (n=9, PICa–V relationship was shifted by −15 mV during UcnII treatment. Conclusion: UcnII exerts positive inotropic and lusitropic effects in cardiomyocytes via CRF2 receptor-mediated stimulation of PKA which augments ICa and SR Ca2+ load to increase SR Ca2+ release and [Ca2+]i transients.